Targeted News Service

AstraZeneca: Enhertu (fam-Trastuzumab Deruxtecan-Nxki) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR-Positive
April 30, 2024

WILMINGTON, Delaware, April 30 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

AstraZeneca and Daiichi Sankyo's ENHERTU also dem . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form